Preclinical activity of selinexor, an inhibitor of XPO1, in sarcomaRobert Nakayama, Andrew J. Wagner, Alex J. Anatone et al.|Oncotarget|2016Cited by 75
Abstract 607: Genomic analyses and novel models validate CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberansAdrián Mariño‐Enríquez, Jonathan A. Fletcher, Grant Eilers et al.|Cancer Research|2015Cited by 0